Key Points
- ADHD diagnosis requires DSM-5 criteria and impairment in ≥2 settings.
- Rule out learning disorders, sleep disorders, mood/anxiety disorders, thyroid abnormalities, and substance misuse.
- Stimulants are first-line for most patients ≥6 years old.
- Behavioral therapy is first-line for preschool-aged children.
- Monitor growth, cardiovascular parameters, and mental health during treatment.
Algorithm
- Identify inattentive and/or hyperactive-impulsive symptoms.
- Obtain collateral history (parents, caregivers, teachers, partners, workplace).
- Assess for comorbid psychiatric, developmental, and medical conditions.
- Exclude mimics (sleep disorders, thyroid dysfunction, mood disorders, substance use).
- Apply DSM-5 criteria and confirm functional impairment in ≥2 settings.
- Initiate behavioral and/or pharmacologic therapy depending on age and severity.
- Monitor response, tolerability, academic/work functioning, and comorbidities.
Clinical Synopsis & Reasoning
ADHD is a chronic neurodevelopmental disorder presenting with patterns of inattention and/or hyperactivity-impulsivity that interfere with functioning or development. Diagnosis is clinical using DSM-5 criteria, requiring ≥6 symptoms (or ≥5 for adults), impairment across ≥2 settings, onset before age 12, and exclusion of mimics such as learning disorders, sleep disorders, anxiety, depression, thyroid disease, and substance use. Core evaluation includes detailed history, collateral information, school/occupational reports, and screening for comorbidities including ODD, learning disorders, mood and anxiety disorders, and autism spectrum disorder.
Treatment Strategy & Disposition
Management integrates behavioral, educational, and pharmacologic strategies. For preschool children, behavior therapy is first line. For school-age children, adolescents, and adults, stimulants (methylphenidate or amphetamine formulations) are first-line, with non-stimulants (atomoxetine, guanfacine ER, clonidine ER, bupropion) used based on tolerability, comorbidities, or contraindications. Coordinate with schools/employers for structured support and academic accommodations. Monitor growth, appetite, sleep, blood pressure, heart rate, and psychiatric symptoms longitudinally.
Epidemiology / Risk Factors
- Affects approximately 5–7% of children globally and persists into adulthood in ~60% of cases.
- High heritability (~70–80%).
- Commonly coexists with learning disorders, anxiety, depression, and sleep disorders.
Investigations
| Assessment | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| Clinical interview + DSM-5 symptom checklist | Primary diagnostic tool | Symptom clusters | Requires impairment in ≥2 settings |
| Collateral reports (parent, teacher, employer) | Confirm cross-setting symptoms | Consistent inattentive or hyperactive-impulsive behavior | Use validated scales (e.g., Vanderbilt, Conners) |
| Screening for comorbidities | Identify co-occurring conditions | Anxiety, learning disorders, mood symptoms | Guides therapy and referral |
| Sleep assessment | Exclude sleep apnea and insomnia | Snoring, poor sleep hygiene | Sleep disorders mimic inattention/hyperactivity |
| Thyroid studies (TSH) as indicated | Exclude thyroid dysfunction | Normal | Check when symptoms atypical or systemic |
| Vision/hearing assessment | Exclude sensory impairment | Normal | Important in children with academic difficulties |
DSM-5 Diagnostic Criteria Overview
| Domain | Criteria |
|---|---|
| Inattention | ≥6 symptoms (≥5 for adults) for ≥6 months, inconsistent with developmental level |
| Hyperactivity/Impulsivity | ≥6 symptoms (≥5 for adults) for ≥6 months |
| Additional Requirements | Symptoms present before age 12, in ≥2 settings, causing impairment, not better explained by another disorder |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Methylphenidate formulations | Block reuptake of dopamine/norepinephrine | Rapid (days) | First-line for most patients | Appetite suppression, insomnia, CV monitoring |
| Amphetamine formulations | Increase synaptic dopamine/norepinephrine | Rapid | First-line alternative | Higher risk of appetite and sleep effects |
| Atomoxetine | Selective norepinephrine reuptake inhibitor | Weeks | Good for anxiety, tic disorders, substance-use risk | Black-box warning for suicidal ideation in youth |
| Guanfacine ER | α2A-agonist improving prefrontal regulation | Weeks | Adjunct for hyperactivity/impulsivity, sleep benefit | Sedation, hypotension |
| Clonidine ER | α2-agonist | Weeks | Adjunct or alternative when stimulants poorly tolerated | Sedation, hypotension |
| Bupropion | Norepinephrine/dopamine reuptake inhibition | Weeks | Useful in adults with depression or smoking cessation | Avoid in seizure disorders |
Prognosis / Complications
- Symptoms often persist but can be effectively managed with structured supports and medications.
- Untreated ADHD increases risk of academic underachievement, occupational impairment, accidents, and mood disorders.
- Early treatment improves long-term academic and psychosocial functioning.
Patient Education / Counseling
- Explain that ADHD is a neurodevelopmental disorder—not a result of poor effort or parenting.
- Discuss medication expectations: onset, duration, monitoring needs, and common side effects.
- Review importance of sleep, physical activity, structured routines, and reduced distractions.
- Collaborate with families/schools/employers for environmental supports.
- Address emotional health, stigma, and potential comorbid conditions.
Notes
ADHD diagnosis requires integration of clinical history, collateral information, and structured rating scales—no single test is diagnostic. Treatment benefits from multimodal strategies including behavioral interventions, medication, environmental modification, and academic/workplace supports. Periodic reassessment is essential due to evolving developmental demands and comorbidities.
References
- American Academy of Pediatrics Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of ADHD in Children and Adolescents (2019) — Link
- National Institute for Health and Care Excellence (NICE) Guideline NG87: Attention Deficit Hyperactivity Disorder (2018, updated) — Link
- Faraone SV et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-Based Conclusions About ADHD. Neurosci Biobehav Rev. 2021. — Link
Meet MDSteps: Smarter USMLE® Prep
MDSteps streamlines your study with an adaptive QBank (19,000+ high-yield MCQs across all 3 Steps), full CCS case simulations for Step 3 with live vitals and timed orders, and an exam-readiness dashboard that turns practice into insight. Build mastery by system and discipline, auto-create missed-item decks (Anki-exportable), and keep momentum with pacing guidance, trend lines, and suggested next sessions—so every block moves you closer to test-day confidence.
Compared with staples like UWorld and AMBOSS, MDSteps aims to give you the best of both worlds: exam-style practice that adapts to you, plus real-time analytics and a full CCS runner—all in one place. If you want targeted, exam-relevant reps with feedback that actually changes how you study, MDSteps is built for you.
Eplore MDSteps